Peptide mapping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-19 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Like eukaryotic protein kinases (ePKs) the different isoforms of the CK1 family consist of a N-terminal and a C-terminal lobe (N- and C-lobe, respectively), which are connected via a hinge region. While the N-lobe is mainly composed by β-sheet strands, the larger C-lobe predominantly consists of α-helical and loop structures. Between both lobes a catalytic cleft is formed, accommodating substrates and ATP for the kinase reaction.
== Contraindications == Contraindications of spironolactone include hyperkalemia (high potassium levels), severe and end-stage kidney disease (due to high hyperkalemia risk, except possibly in those on dialysis), Addison's disease (adrenal insufficiency and low aldosterone levels), and concomitant use of eplerenone. It should also be used with caution in people with certain neurological disorders, as well as those who experience or have experienced anuria (lack of urine production), acute kidney injury, or significant impairment of kidney excretory function with risk of hyperkalemia.
=== 2 May === Russian Defence Minister Sergei Shoigu said that Russian success in Ukraine would "largely depend on the timely replenishment of weapons". He said that the Russian army had the weapons that it needed for 2023, nevertheless he asked a rocket producer to double its manufacture of precision missiles.
Sources: en.wikipedia.org
=== Sensitive sweat test === The sensitive sweat test (SST) was developed by Adam Loavenbruck and colleagues in 2017 for the evaluation of individual sweat glands. It allows for the quantification of sweat from each individual sweat gland, as well as their location and distribution, thus providing both temporal and spatial resolution. The procedure is initiated by the iontophoresis of 0.5% pilocarpine solution over a 2.25 cm2 skin area, which stimulates the underlying sweat glands directly through the activation of muscarinic M3 receptors. Immediately following iontophoresis, the skin is dried, and then covered with a 10% povidone-iodine solution. At the onset of sweating, the reaction of sweat with the povidone-iodine solution and corn starch results in the appearance of a black spot. A customized miniature camera can follow the secretions of up to 400 sweat glands at a time for up to 60 seconds, analyzing the enlargement rate and area of each spot. The test is then repeated for replicate analysis. The procedure is relatively quick and the camera is portable. However, further testing is needed to establish normative data and to confirm its utility in autonomic testing. As the test lacks an axon-reflex response, it has a limited ability to assess nerve fiber function.
The discovery of nuclear fission occurred in 1938 in the buildings of the Kaiser Wilhelm Society for Chemistry, today part of the Free University of Berlin, following over four decades of work on the science of radioactivity and the elaboration of new nuclear physics that described the components of atoms. In 1911, Ernest Rutherford proposed a model of the atom in which a very small, dense and positively charged nucleus of protons was surrounded by orbiting, negatively charged electrons (the Rutherford model). Niels Bohr improved upon this in 1913 by reconciling the quantum behavior of electrons (the Bohr model). In 1928, George Gamow proposed the liquid-drop model, which became essential to understanding the physics of fission. In 1896, Henri Becquerel had found, and Marie Curie named, radioactivity. In 1900, Rutherford and Frederick Soddy, investigating the radioactive gas emanating from thorium, "conveyed the tremendous and inevitable conclusion that the element thorium was slowly and spontaneously transmuting itself into argon gas!" In 1919, following up on an earlier anomaly Ernest Marsden noted in 1915, Rutherford attempted to "break up the atom." Rutherford was able to accomplish the first artificial transmutation of nitrogen into oxygen, using alpha particles directed at nitrogen 14N + α → 17O + p. Rutherford stated, "...we must conclude that the nitrogen atom is disintegrated," while the newspapers stated he had split the atom.
==== Combination drugs ==== Carbidopa/entacapone/levodopa (LECIGel; LECIGon; Lecigon; Trigel) – combination of carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor), entacapone (catechol O-methyltransferase (COMT) inhibitor), and levodopa (dopamine precursor) [345] Levodopa/carbidopa/entacapone (ELC-200; Stalevo; Stavelo) – combination of levodopa (dopamine precursor), carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor), and entacapone (catechol O-methyltransferase (COMT) inhibitor) [346]
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.